Yanan Zhu
Stock Analyst at Wells Fargo
(2.04)
# 2,979
Out of 5,090 analysts
84
Total ratings
35.71%
Success rate
-2.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Overweight | $80 → $60 | $21.33 | +181.29% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $17 → $12 | $9.61 | +24.87% | 7 | Nov 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $50 → $45 | $22.26 | +102.16% | 7 | Nov 5, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $48 → $72 | $34.47 | +108.91% | 7 | Nov 3, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $7.13 | +180.50% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.42 | +65.29% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $35.26 | +27.62% | 1 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $82 | $81.68 | +0.39% | 3 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $16 → $12 | $1.78 | +574.16% | 4 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $5.05 | +58.42% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.08 | +131.48% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.55 | +222.58% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $2.20 | +536.36% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $71.63 | +4.70% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $27.09 | +158.40% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.28 | +133.64% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $33.45 | +19.58% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $56.88 | +14.28% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.07 | +271.75% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.50 | +706.61% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.61 | +12,365.37% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $901.17 | -63.82% | 1 | Feb 2, 2021 |
uniQure
Nov 12, 2025
Maintains: Overweight
Price Target: $80 → $60
Current: $21.33
Upside: +181.29%
Intellia Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $17 → $12
Current: $9.61
Upside: +24.87%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $22.26
Upside: +102.16%
RAPT Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $48 → $72
Current: $34.47
Upside: +108.91%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $7.13
Upside: +180.50%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.42
Upside: +65.29%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $35.26
Upside: +27.62%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $77 → $82
Current: $81.68
Upside: +0.39%
Metagenomi
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.78
Upside: +574.16%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $5.05
Upside: +58.42%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.08
Upside: +131.48%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.55
Upside: +222.58%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.20
Upside: +536.36%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $71.63
Upside: +4.70%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $27.09
Upside: +158.40%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.28
Upside: +133.64%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $33.45
Upside: +19.58%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $56.88
Upside: +14.28%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $8.07
Upside: +271.75%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.50
Upside: +706.61%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $3.61
Upside: +12,365.37%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $901.17
Upside: -63.82%